Heat Biologics, Inc. (NASDAQ:HTBX) Scheduled to Post Quarterly Earnings on Monday
Heat Biologics, Inc. (NASDAQ:HTBX) is scheduled to be announcing its earnings results on Monday, August 14th. Analysts expect the company to announce earnings of ($0.10) per share for the quarter.
Shares of Heat Biologics, Inc. (NASDAQ HTBX) traded up 1.9792% during mid-day trading on Friday, hitting $0.4998. 119,020 shares of the stock were exchanged. The stock’s market capitalization is $17.80 million. The stock’s 50-day moving average is $0.55 and its 200-day moving average is $0.75. Heat Biologics, Inc. has a 52 week low of $0.46 and a 52 week high of $3.35.
COPYRIGHT VIOLATION WARNING: “Heat Biologics, Inc. (NASDAQ:HTBX) Scheduled to Post Quarterly Earnings on Monday” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another site, it was copied illegally and reposted in violation of United States & international trademark and copyright law. The correct version of this article can be read at https://www.americanbankingnews.com/2017/08/11/heat-biologics-inc-nasdaqhtbx-scheduled-to-post-quarterly-earnings-on-monday.html.
Several equities analysts recently commented on the stock. ValuEngine cut shares of Heat Biologics from a “sell” rating to a “strong sell” rating in a research note on Thursday, July 13th. Zacks Investment Research cut shares of Heat Biologics from a “buy” rating to a “hold” rating in a research note on Wednesday, July 12th. Finally, Noble Financial reaffirmed a “buy” rating on shares of Heat Biologics in a research note on Tuesday, July 4th.
An institutional investor recently raised its position in Heat Biologics stock. Vanguard Group Inc. boosted its stake in shares of Heat Biologics, Inc. (NASDAQ:HTBX) by 11.9% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 661,388 shares of the biopharmaceutical company’s stock after buying an additional 70,290 shares during the period. Vanguard Group Inc. owned about 1.86% of Heat Biologics worth $403,000 at the end of the most recent reporting period. 10.06% of the stock is currently owned by institutional investors and hedge funds.
Heat Biologics Company Profile
Heat Biologics, Inc is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT).
Receive News & Ratings for Heat Biologics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.